切换至 "中华医学电子期刊资源库"
高级检索
中华腔镜外科杂志(电子版)

中华腔镜外科杂志(电子版) ›› 2023, Vol. 16 ›› Issue (06) : 325 -330. doi: 10.3877/cma.j.issn.1674-6899.2023.06.002

论著

Ⅳ期卵巢癌患者经微创或开腹行间歇性肿瘤细胞减灭术的临床分析
张同乐, 王铭洋, 李立安, 孟元光, 叶明侠†()   
  1. 100853　北京，中国人民解放军总医院第一医学中心妇产科；300071　天津，南开大学医学院
    100853　北京，中国人民解放军总医院第一医学中心妇产科
  • 收稿日期:2023-11-03 出版日期:2023-12-30
  • 通信作者: 叶明侠
  • 基金资助:
    国家重点研发计划(2017YFC0110405)

Clinical analysis of interval debulking surgery via MIS versus laparotomy in stage IV ovarian cancer patients

Tongle Zhang, Mingyang Wang, Li′an Li, Yuanguang Meng, Mingxia Ye†()   

  1. Department of Gynecology and Obstetrics, the First Medical Center of Chinese People′s Liberation Army (PLA) General Hospital, Beijing 100853, China; School of Medicine, Nankai University, Tianjin 300071, China
    Department of Gynecology and Obstetrics, the First Medical Center of Chinese People′s Liberation Army (PLA) General Hospital, Beijing 100853, China
  • Received:2023-11-03 Published:2023-12-30
  • Corresponding author: Mingxia Ye
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

张同乐, 王铭洋, 李立安, 孟元光, 叶明侠. Ⅳ期卵巢癌患者经微创或开腹行间歇性肿瘤细胞减灭术的临床分析[J/OL]. 中华腔镜外科杂志(电子版), 2023, 16(06): 325-330.

Tongle Zhang, Mingyang Wang, Li′an Li, Yuanguang Meng, Mingxia Ye. Clinical analysis of interval debulking surgery via MIS versus laparotomy in stage IV ovarian cancer patients[J/OL]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2023, 16(06): 325-330.

目的

比较Ⅳ期卵巢癌患者经微创(minimally invasive surgery, MIS)与开腹方式行间歇性肿瘤细胞减灭术(interval debulking surgery, IDS)的围术期指标和生存结局。

方法

本研究采用回顾性研究方法，纳入2017年1月至2021年12月在解放军总医院第一医学中心行IDS所有确诊为Ⅳ期卵巢癌的患者98例，根据手术方式分为开腹组74例和微创组24例，收集两组患者的围术期临床指标并进行随访，比较两组临床疗效和生存结局。

结果

微创组与开腹组IDS患者的临床基线均衡可比，两组的术中操作、手术时间和术后残留病灶的差异无统计学意义。微创组比开腹组预估失血量更少，术中输血率更低，术后恢复和开始辅助化疗的时间更短(以上均P<0.001)。共82.7%患者通过IDS达到满意的肿瘤细胞减灭效果，微创组与开腹组的术后残留病灶差异无统计学意义(P<0.05)。微创组患者的医疗费用更高(P<0.001)。两组患者的无进展生存期和总生存期差异无统计学意义(P＝0.998和P＝0.592)。

结论

对于新辅助化疗(neoadjuvant chemotherapy，NACT)后行IDS的Ⅳ期卵巢癌患者，经过评估后选择微创IDS是技术上可行的手术方式，能达到满意的肿瘤细胞减灭效果，并且能减少术中出血及损伤，缩短术后恢复时间和开始化疗的时间，在一定程度上使患者获益。

关键词: 卵巢癌, 间歇性肿瘤细胞减灭术, 微创手术, Ⅳ期卵巢癌
Objective

This study aimed to assess perioperative and survival outcomes of minimally invasive surgery(MIS) compared to standard laparotomy interval debulking surgery(IDS) for stage IV ovarian cancer.

Methods

A retrospective study was applied in this study. All patients diagnosed with stage IV ovarian cancer who underwent IDS at the People′s Liberation Army General Hospital from Jan. 2017 to Dec. 2021 were included. According to surgical approaches, patients were divided into laparotomy(n=74) and MIS(n=24) cohorts. We collected perioperative indicators and follow-up information and then made statistical analyses to compare clinical efficacy and survival outcome.

Results

The clinical baseline of IDS patients in the MIS cohort was comparable to that the open cohort. No statistical differences were observed for surgical procedures, operation time and residual diseases. Compared with the laparotomy group, the MIS group had more favorable estimated blood loss, transfusion rate, duration of postoperative recovery and adjuvant chemotherapy(above P<0.001) as well as fewer intraoperative complications (P<0.05). 82.7% of the whole were optimally cytoreductive and there was no significant difference in residual diseases(P<0.05). Nevertheless, MI-IDS patients afforded higher medical expense(P<0.001). Besides, progression-free survival and overall survival had no statistical difference(P=0.998 and 0.592, respectively).

Conclusion

For stage IV ovarian cancer patients after NACT, minimally invasive IDS could represent a technically feasible alternative surgical choice with optimal cytoreduction. It could reduce intraoperative bleeding and injury, shorten postoperative recovery duration and time to chemotherapy, which benefit patients to some extent.

Key words: Ovarian cancer, Interval debulking surgery, Minimally invasive surgery, Stage Ⅳ ovarian cancer
图1 患者纳入、排除流程图
表1 开腹组与微创组患者术前基线特征比较
基线特征 开腹组(n＝74) 微创组(n＝24) t/χ2/Z值 P值
年龄(岁，±s) 55.0±10.3 54.5±11.4 0.201 0.841
BMI(kg/m2，±s) 23.7±3.2 22.9±2.5 1.178 0.242
ASA评分[例(%)]     0.360 0.549
2 67(90.5) 20(83.3)    
3 7(9.5) 4(16.7)    
肿瘤病史[例(%)] 5(6.8) 1(4.2) 0.000 >0.999
盆腹部手术史[例(%)] 37(50) 12(50) 0.000 >0.999
确诊时CA125(UI/ml) 1000(422，2170) 1749(804，3413) －2.359 0.018
术前CA125(UI/ml) 46.5(15.1，154.2) 70.4(24.2，167.2) －0.537 0.591
NACT程数(±s) 2.7±1.1 3.4±1.7 －1.776 0.076
Ⅳ期证据[例(%)]     3.302 0.192
胸腔积液 9(12.2) 1(4.2)    
腹腔脏器实质 18(24.3) 10(41.7)    
腹膜外转移 47(63.5) 13(54.2)    
浆液性癌[例(%)] 70 (94.6) 22 (91.7) 0.001 0.976
表2 开腹IDS与微创IDS术中相关指标比较
指标 开腹组(n＝74) 微创组(n＝24) t/χ2/Z值 P值
妇科手术操作[例(%)]     0.304 0.582
(全子宫)双附件大网膜切除术 59(79.7) 21(87.5)    
(全子宫)双附件大网膜切除及淋巴结清扫术 15(20.3) 3(12.5)    
减瘤手术分类[例(%)]     1.202 0.627
Ⅰ类 61(82.4) 22(91.7)    
Ⅱ类及以上 12(16.2) 2(8.3)    
手术时长(min，±s) 257±93 294±105 －1.684 0.095
术中出血量(ml) 600(400，1000) 200(100，300) －5.219 <0.001
术中输血[例(%)] 48(64.9) 3(12.5) 19.910 <0.001
术中并发症[例(%)] 13(17.6) 0(0) 3.454 0.063
残留病灶[例(%)]     3.328 0.189
R0 49(66.2) 12(50)    
R1 15(20.3) 5(20.8)    
R2 10(13.5) 7(29.2)    
表3 三组术后恢复指标和费用比较
指标 开腹组(n＝74) 微创组(n＝24) t/χ2/Z值 P值
肛门排气时间(d) 3.00(2.50，4.00) 2.00(1.25，3.00) －4.062 <0.001
术后住院时间(d) 12(10，16) 9(8，11) －3.967 <0.001
术后化疗时间(d) 10(9，14) 7(6，9) －5.049 <0.001
术后并发症[例(%)] 36(48.6) 8(33.3) 1.718 0.190
手术费用(元，±s) 8728±7065 23304±17510 －3.518 <0.001
住院费用(元，±s) 61625±24912 66969±19174 －1.733 0.083
图2 开腹IDS组和微创IDS组术后PFS生存分析函数
图3 开腹IDS组和微创IDS组术后OS生存分析函数
1
Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review[J]. Semin Oncol Nurs, 2019, 35(2)：151-156.
2
中国抗癌协会妇科肿瘤专业委员会. 卵巢恶性肿瘤诊断与治疗指南(2021年版)[J]. 中国癌症杂志，2021，31(6)：490-500.
3
Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial[J]. Lancet, 2021, 397(10290)：2182-2193.
4
Castro BGR, Dos Reis R, Cintra GF, et al. Predictive factors for surgical morbidities and adjuvant chemotherapy delay for advanced ovarian cancer patients treated by primary debulking surgery or interval debulking surgery[J]. Int J Gynecol Cancer, 2018, 28(8)：1520-1528.
5
Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial[J]. Lancet, 2015, 386(9990)：249-257.
6
Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage ⅢC or Ⅳ ovarian cancer[J]. N Engl J Med, 2010, 363(10)：943-953.
7
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(2)：191-226.
8
Dabi Y, Huchon C, Ouldamer L, et al. Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival[J]. J Transl Med, 2020, 18(1)：134.
9
Sørensen SM, Høgdall C, Mosgaard BJ, et al. Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer[J]. Acta Obstet Gynecol Scand, 2022, 101(3)：334-343.
10
卢淮武，叶栋栋，吴斌，等. 《2023 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志，2023, 39(1)：58-67.
11
Nelson G, Altman AD, Nick A, et al. Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations-Part I[J]. Gynecol Oncol, 2016, 140(2)：313-322.
12
Jamieson A, Sykes P, Eva L, et al. Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence[J]. Gynecol Oncol, 2017, 146(2)：273-278.
13
Magrina JF, Zanagnolo V, Noble BN, et al. Robotic approach for ovarian cancer: perioperative and survival results and comparison with laparoscopy and laparotomy[J]. Gynecol Oncol, 2011, 121(1)：100-105.
14
中华妇产科杂志编委会，中华医学会妇产科学分会妇科肿瘤学组. 复发性卵巢恶性肿瘤的诊治规范(建议)[J]. 中华妇产科杂志，2003, 38(11)：717-719.
15
Kuusela K, Norppa N, Auranen A, et al. Maximal surgical effort increases the risk of postoperative complications in the treatment of advanced ovarian cancer[J]. Eur J Surg Oncol, 2022, 48(12)：2525-2530.
16
Gueli Alletti S, Petrillo M, Vizzielli G, et al. Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study[J]. Gynecol Oncol, 2016, 143(3)：516-520.
17
Makar AP, Tropé CG, Tummers P, et al. Advanced ovarian cancer: primary or interval debulking? Five categories of patients in view of the results of randomized trials and tumor biology: primary debulking surgery and interval debulking surgery for advanced ovarian cancer[J]. Oncologist, 2016, 21(6)：745-754.
18
Tang Q, Liu W, Jiang D, et al. Perioperative and survival outcomes of robotic-assisted surgery, comparison with laparoscopy and laparotomy, for ovarian cancer: a network meta-analysis[J]. J Oncol, 2022, 2022：2084774.
19
Vincent L, Jankowski C, Ouldamer L, et al. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group[J]. Eur J Surg Oncol, 2020, 46(9)：1689-1696.
20
Cardenas-Goicoechea J, Wang Y, McGorray S, et al. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis[J]. J Robot Surg, 2019, 13(1)：23-33.
21
Timmermans M, van der Aa MA, Lalisang RI, et al. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer[J]. Gynecol Oncol, 2018, 150(3)：446-450.
22
Clair KH, Tewari KS. Robotic surgery for gynecologic cancers: indications, techniques and controversies[J]. J Obstet Gynaecol Res, 2020, 46(6)：828-843.
23
Zhang Y, Grant MS, Zhang X, et al. Comparing laparotomy with robot-assisted interval debulking surgery for patients with advanced epithelial ovarian cancer receiving neoadjuvant chemotherapy[J]. J Minim Invasive Gynecol, 2021, 28(6)：1237-1243.
24
Ackroyd SA, Thomas S, Angel C, et al. Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer[J]. J Robot Surg, 2018, 12(2)：245-250.
[1] 朱洪宇, 曹越, 赵鑫洋, 周毅. 三孔全腔镜手术治疗中重度男性乳房发育症[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(03): 152-157.
[2] 中华医学会器官移植学分会, 中国医师协会器官移植医师分会. 中国活体肝移植供者微创手术技术指南（2024版）[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 241-252.
[3] 中华医学会器官移植学分会, 中国医师协会器官移植医师分会. 中国活体肝移植供者微创手术技术指南(2024年版)[J/OL]. 中华移植杂志(电子版), 2024, 18(02): 74-85.
[4] 蒋露, 郑莹, 杨帆, 王乔, 王娜, 阳川华, 陈宇, 苟嘉妮, 邓露丝, 杨旭. 经脐单孔腹腔镜联合上腹部开腹行晚期卵巢癌肿瘤细胞减灭术[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(03): 177-181.
[5] 罗洋, 谢小龙, 向波. 儿童腔镜辅助胆总管囊肿切除术胆肠吻合处理策略研究[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(02): 70-75.
[6] 曾纪晓, 梁子建. 单孔腹腔镜手术在儿童普通外科中的应用与展望[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(02): 65-69.
[7] 张宗明, 董家鸿, 何小东, 王秋生, 徐智, 刘立民, 张翀. 老年胆道外科热点问题的争议与思考[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 754-762.
[8] 曹文钰, 郭鹏, 李锦平. 微创手术及非手术方式治疗慢性硬膜下血肿的研究进展[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 304-309.
[9] 李新宇, 梁建锋. 3D打印导板辅助颅内血肿穿刺引流手术[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(06): 382-384.
[10] 徐靖亭, 孔璐. PARP抑制剂治疗卵巢癌的耐药机制及应对策略[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 584-588.
[11] 朱芮晴, 张荣贵, 冯秀雪, 张波, 刘圣圳, 柴宁莉, 令狐恩强. 基于倾向性评分匹配法的日间消化内镜超级微创手术治疗直肠神经内分泌肿瘤的疗效评价[J/OL]. 中华胃肠内镜电子杂志, 2024, 11(03): 166-170.
[12] 蔡朝蓓, 陈倩倩, 宁波, 李惠凯, 袁新普, 令狐恩强. 超级微创手术模式与器官切除模式下结直肠癌患者的生活质量和心理状态变化[J/OL]. 中华胃肠内镜电子杂志, 2024, 11(02): 81-87.
[13] 蔡朝蓓, 陈倩倩, 令狐恩强. 辅助牵引技术在消化道肿瘤超级微创手术中的研究进展[J/OL]. 中华胃肠内镜电子杂志, 2024, 11(01): 52-55.
[14] 鲍颖慧, 李伯妍, 周宁, 尹晓岳, 赵敏, 朱国宁, 刘淼, 何耀. 基于卫生经济学评价报告标准评价消化道肿瘤微创手术卫生经济学研究的报告规范性[J/OL]. 中华胃肠内镜电子杂志, 2024, 11(01): 41-46.
[15] 沈海锋, 吕方伊, 顾海华, 常志博, 陈盈, 王苹莉, 吴祖群, 邱福铭, 姚杰, 范军强. 局部进展期肺癌新辅助治疗后胸腔镜袖式肺叶切除术——浙江大学医学院附属第二医院2014—2023年56例回顾性分析[J/OL]. 中华胸部外科电子杂志, 2024, 11(03): 158-166.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号